Novel therapies for HIV patients who have failed anti-retroviral therapies & 12th Anniversary of the B2DG-Ramani Aiyer-04/14/2015 - 6:00pm

Event Information
Event Topic: 
Novel therapies for HIV patients who have failed anti-retroviral therapies & 12th Anniversary of the B2DG
Event Date: 
04/14/2015 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Ramani Aiyer
Event Speaker Title: 
Principal
Event Speaker Company: 
Shasta Bioventures
Event Speaker Bio: 

Ramani A. Aiyer heads Shasta BioVentures, a Life Sciences R&D and Business Development consultancy offering strategic advisory and project management services. Currently, he serves part-time as Chief Scientific Officer of STAR Biotech, a start-up focused on discovery and development of novel therapies for Ewing’s Sarcoma. Ramani has a PhD in Biochemistry from Harvard, did post-doctoral research at Stanford and Dana-Farber Cancer Institute, and MBA from University of California, Berkeley. He has over 20 years’ experience in the bio-pharmaceutical industry, with major roles in R&D strategic planning, mentoring scientists and leading project teams. Earlier, Ramani was Chief Scientific Officer at Actis Biologics (INDIA), a start-up bio-therapeutics company, and prior to that Senior Vice President, R&D Strategic Planning at Piramal Life Sciences (INDIA). Ramani’sother roles have included management consulting, and senior positions at Genentech, TransMed Biotech, LifeScan (acquired by Johnson & Johnson), and Sugen (acquired by Pharmacia/Pfizer.

Event Details
Cost: 
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

Anti-retroviral therapies (ART) have revolutionized treatment options for HIV patients giving them a new lease of life from what used to be essentially a death warrant when found to be infected with HIV. Of the 2 million HIV-infected patients in US and EU, about 100,000 (5%) fail ART for a variety of reasons and will eventually succumb to the disease. This is a vast unmet need and the talk will focus on current approaches to meet this challenge. In particular, the talk will describe the efforts at TheraBiol Inc.(http://www.therabiol.com), a Bay area start-up founded in May 2012 by a core group of scientists, physicians and entrepreneurs with the support of the QB3 Incubator Program (www.qb3.org) at UCSF. The company is headed by Dr. Girish N. Vyas, Founder & CEO, who is Emeritus Professor at UCSF and a world authority on Virology and Transfusion Medicine.

Payment Options Dec 12th Evening Event

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address